Literature DB >> 15143930

A mixed hepatocellular carcinoma and cholangiocarcinoma: dual expression of biliary-type cytokeratin and hepatocyte specific marker.

Shogo Tanaka1, Kazuhiro Hirohashi, Takahiro Uenishi, Takatsugu Yamamoto, Hiroyuki Hamba, Shoji Kubo, Hiromu Tanaka, Taichi Shuto, Masao Ogawa, Hiroaki Kinoshita.   

Abstract

A 5-cm lesion in the right hepatic lobe was detected in a 61-year-old man with chronic hepatitis C by ultrasonography. Contrast-enhanced computed tomography showed a low-density lesion with wide peripheral enhancement. Hepatic angiography revealed that the tumor had partial hypervascularity. Although serum concentrations of alpha-fetoprotein and carcinoembryonic antigen were within normal limits, an elevated concentration of carcinohydrate antigen 19-9 was detected in serum. A definitive diagnosis was not made although we strongly suspected mixed hepatocellular carcinoma and cholangiocarcinoma. Since intraoperative frozen-section examination revealed adenocarcinoma, a right hepatic lobectomy with regional lymph node dissection was performed. A histologic diagnosis of mixed hepatocellular carcinoma and cholangiocarcinoma was made because the hepatic tumor consisted of components of both hepatocellular carcinoma and cholangiocellular carcinoma, with a transitional area. Additionally, immunohistochemical examination revealed that some tumor cells in the transitional area were immunoreactive for both cytokeratin 19 and hepatocyte paraffin 1.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15143930

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  1 in total

1.  Proteomic expression signature distinguishes cancerous and nonmalignant tissues in hepatocellular carcinoma.

Authors:  Nikki P Lee; Lei Chen; Marie C Lin; Felice H Tsang; Chun Yeung; Ronnie T Poon; Jirun Peng; Xisheng Leng; Laura Beretta; Stella Sun; Philip J Day; John M Luk
Journal:  J Proteome Res       Date:  2009-03       Impact factor: 4.466

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.